Is it Getting Breezy In Here? Biotech IPO Climate Improving

Don't look now, biotech IPO prices are getting better. But VCs still prefer M&A. Here's a look at biotech IPOs from the past two years: average cash raised, total cash raised and total successful IPOs.

Although biotech M&A exits continue to be more profitable than the public markets for venture investors, the pace of initial public offerings has picked up noticeably in recent months. Indeed, in recent weeks Precision Therapeutics Inc. , Archemix Corp. , and Biolex Inc. have all filed to go public. [See Deal][See Deal][See Deal] But not only have more IPOs been filed over the past twelve months than the preceding twelve months, the more recent IPOs have collectively raised over 50% more: roughly $1.4 billion from September 2005 through August 2006 compared with $2.1 billion in the past twelve months. (See Exhibit 1.)

This uptick in fundraising has little to do with the increasing pace of IPO filings however; though there were 61...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.